Position
MARSHALL WACE, LLP in Neumora Therapeutics, Inc.
Back to the book · All holders of NMRA
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $93.4K$1.79 → $1.95
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 583.8K | $1.04M | — | — | — | 0.0% |
| Q1 2026 | 1.2M | $2.33M | $1.95 | $93.4K | $1.19M | 0.0% |